ENTX vs. MGX, CADL, IVVD, GLUE, SCLX, CHRS, ELEV, FENC, CGEN, and ZURA
Should you be buying Entera Bio stock or one of its competitors? The main competitors of Entera Bio include Metagenomi (MGX), Candel Therapeutics (CADL), Invivyd (IVVD), Monte Rosa Therapeutics (GLUE), Scilex (SCLX), Coherus BioSciences (CHRS), Elevation Oncology (ELEV), Fennec Pharmaceuticals (FENC), Compugen (CGEN), and Zura Bio (ZURA). These companies are all part of the "biological products, except diagnostic" industry.
Metagenomi (NASDAQ:MGX) and Entera Bio (NASDAQ:ENTX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, community ranking, institutional ownership, profitability, earnings, dividends, media sentiment, valuation and analyst recommendations.
Metagenomi currently has a consensus target price of $17.83, suggesting a potential upside of 194.77%. Entera Bio has a consensus target price of $10.00, suggesting a potential upside of 356.62%. Given Metagenomi's stronger consensus rating and higher possible upside, analysts plainly believe Entera Bio is more favorable than Metagenomi.
Entera Bio has lower revenue, but higher earnings than Metagenomi.
Entera Bio's return on equity of 0.00% beat Metagenomi's return on equity.
14.1% of Entera Bio shares are owned by institutional investors. 8.9% of Entera Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Entera Bio received 166 more outperform votes than Metagenomi when rated by MarketBeat users. However, 90.00% of users gave Metagenomi an outperform vote while only 67.05% of users gave Entera Bio an outperform vote.
In the previous week, Entera Bio had 4 more articles in the media than Metagenomi. MarketBeat recorded 5 mentions for Entera Bio and 1 mentions for Metagenomi. Entera Bio's average media sentiment score of 1.89 beat Metagenomi's score of 0.81 indicating that Metagenomi is being referred to more favorably in the media.
Summary
Entera Bio beats Metagenomi on 8 of the 14 factors compared between the two stocks.
Get Entera Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for ENTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ENTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Entera Bio Competitors List
Related Companies and Tools
